Elanco Animal Health Incorporated (NYSE:ELAN) Shares Purchased by Atom Investors LP

Atom Investors LP raised its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 310.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 345,855 shares of the company’s stock after purchasing an additional 261,559 shares during the quarter. Atom Investors LP owned 0.07% of Elanco Animal Health worth $5,081,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of ELAN. Commerce Bank raised its holdings in Elanco Animal Health by 2.2% during the third quarter. Commerce Bank now owns 35,114 shares of the company’s stock worth $516,000 after purchasing an additional 741 shares in the last quarter. 180 Wealth Advisors LLC lifted its holdings in shares of Elanco Animal Health by 3.6% in the 2nd quarter. 180 Wealth Advisors LLC now owns 25,716 shares of the company’s stock valued at $352,000 after buying an additional 893 shares during the period. HBK Sorce Advisory LLC boosted its stake in shares of Elanco Animal Health by 9.4% in the second quarter. HBK Sorce Advisory LLC now owns 12,920 shares of the company’s stock valued at $186,000 after buying an additional 1,107 shares in the last quarter. Atomi Financial Group Inc. grew its holdings in Elanco Animal Health by 11.1% during the second quarter. Atomi Financial Group Inc. now owns 12,260 shares of the company’s stock worth $177,000 after acquiring an additional 1,221 shares during the period. Finally, Keene & Associates Inc. raised its position in Elanco Animal Health by 5.7% in the third quarter. Keene & Associates Inc. now owns 22,945 shares of the company’s stock worth $337,000 after acquiring an additional 1,240 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on ELAN shares. Barclays boosted their target price on shares of Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, November 8th. Morgan Stanley lowered shares of Elanco Animal Health from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $17.00 to $15.00 in a research report on Thursday, September 19th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $20.00 price target on shares of Elanco Animal Health in a research report on Thursday, September 19th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Elanco Animal Health presently has an average rating of “Hold” and an average target price of $17.14.

Elanco Animal Health Stock Up 0.6 %

Shares of NYSE ELAN opened at $13.21 on Monday. The firm’s 50-day moving average is $13.57 and its two-hundred day moving average is $14.63. The company has a market capitalization of $6.53 billion, a PE ratio of 33.03, a price-to-earnings-growth ratio of 1.38 and a beta of 1.41. Elanco Animal Health Incorporated has a 12-month low of $11.40 and a 12-month high of $18.80. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Thursday, November 7th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.01. The firm had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.04 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. Elanco Animal Health’s revenue was down 3.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.18 EPS. Equities analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.